Finance Cramer: Valeant fuss a ‘travesty’By DeepApril 15, 20160 The situation surrounding Valeant Pharmaceuticals has transformed the company into a “great mystery,” CNBC’s Jim Cramer said Monday. “The numbers…
Finance Valeant cuts 2016 revenue forecastBy DeepApril 13, 20160 Shares of Valeant Pharmaceuticals tumbled on Tuesday after the company cut its 2016 revenue forecast by about 12 percent and…
